OnKure Therapeutics, Inc. (NASDAQ: OKUR) Stock Competitors & Peer Comparison
See OKUR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for OKUR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| OKUR | $3.09 | +4.75% | 123.9M | -0.87 | -$3.50 | N/A |
| VRTX | $520.71 | +2.43% | 129.6B | 26.83 | $19.03 | N/A |
| REGN | $810.99 | +3.33% | 82.2B | 17.49 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| MRNA | $183.50 | +19.12% | 68.6B | -21.22 | -$8.15 | N/A |
| ARGX | $973.06 | -1.74% | 61.5B | 35.63 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $192.70 | +0.92% | 41B | -21.85 | -$8.82 | N/A |
| RVMDW | $9.97 | +3.37% | 39.3B | -1.13 | -$8.82 | N/A |
| ONC | $367.13 | +4.64% | 39.1B | 64.38 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
OKUR vs VRTX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, VRTX has a market cap of 129.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while VRTX trades at $520.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas VRTX's P/E ratio is 26.83. In terms of profitability, OKUR's ROE is -0.49%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, OKUR is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
OKUR vs REGN Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, REGN has a market cap of 82.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while REGN trades at $810.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas REGN's P/E ratio is 17.49. In terms of profitability, OKUR's ROE is -0.49%, compared to REGN's ROE of +0.14%. Regarding short-term risk, OKUR is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
OKUR vs VRNA Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas VRNA's P/E ratio is -102.80. In terms of profitability, OKUR's ROE is -0.49%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, OKUR is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check VRNA's competition here
Moderna, Inc. (NASDAQ: MRNA)
OKUR vs MRNA Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, MRNA has a market cap of 68.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while MRNA trades at $183.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas MRNA's P/E ratio is -21.22. In terms of profitability, OKUR's ROE is -0.49%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, OKUR is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check MRNA's competition here
argenx SE (NASDAQ: ARGX)
OKUR vs ARGX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ARGX has a market cap of 61.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ARGX trades at $973.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ARGX's P/E ratio is 35.63. In terms of profitability, OKUR's ROE is -0.49%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, OKUR is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
OKUR vs SGEN Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas SGEN's P/E ratio is -57.19. In terms of profitability, OKUR's ROE is -0.49%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, OKUR is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
OKUR vs RVMD Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, RVMD has a market cap of 41B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while RVMD trades at $192.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas RVMD's P/E ratio is -21.85. In terms of profitability, OKUR's ROE is -0.49%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, OKUR is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
OKUR vs RVMDW Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, RVMDW has a market cap of 39.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while RVMDW trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas RVMDW's P/E ratio is -1.13. In terms of profitability, OKUR's ROE is -0.49%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, OKUR is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
OKUR vs ONC Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ONC has a market cap of 39.1B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ONC trades at $367.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ONC's P/E ratio is 64.38. In terms of profitability, OKUR's ROE is -0.49%, compared to ONC's ROE of +0.14%. Regarding short-term risk, OKUR is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
OKUR vs ALNY Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ALNY has a market cap of 32.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ALNY trades at $254.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ALNY's P/E ratio is 44.02. In terms of profitability, OKUR's ROE is -0.49%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, OKUR is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
OKUR vs ROIV Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ROIV has a market cap of 28.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ROIV trades at $38.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ROIV's P/E ratio is -37.09. In terms of profitability, OKUR's ROE is -0.49%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, OKUR is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
OKUR vs INSM Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, INSM has a market cap of 26.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while INSM trades at $121.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas INSM's P/E ratio is -29.44. In terms of profitability, OKUR's ROE is -0.49%, compared to INSM's ROE of -1.11%. Regarding short-term risk, OKUR is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
OKUR vs INCY Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, INCY has a market cap of 25.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while INCY trades at $127.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas INCY's P/E ratio is 16.75. In terms of profitability, OKUR's ROE is -0.49%, compared to INCY's ROE of +0.30%. Regarding short-term risk, OKUR is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
OKUR vs BNTX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, BNTX has a market cap of 24.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while BNTX trades at $101.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas BNTX's P/E ratio is -12.71. In terms of profitability, OKUR's ROE is -0.49%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, OKUR is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
OKUR vs GMAB Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while GMAB trades at $35.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas GMAB's P/E ratio is 26.14. In terms of profitability, OKUR's ROE is -0.49%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, OKUR is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
OKUR vs UTHR Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, UTHR has a market cap of 20.9B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while UTHR trades at $498.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas UTHR's P/E ratio is 17.64. In terms of profitability, OKUR's ROE is -0.49%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, OKUR is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
OKUR vs BGNE Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas BGNE's P/E ratio is -22.55. In terms of profitability, OKUR's ROE is -0.49%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, OKUR is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
OKUR vs DNA-WT Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, OKUR's ROE is -0.49%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, OKUR is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
OKUR vs JAZZ Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, JAZZ has a market cap of 15.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while JAZZ trades at $240.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas JAZZ's P/E ratio is 9.00. In terms of profitability, OKUR's ROE is -0.49%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, OKUR is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
OKUR vs ASND Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ASND trades at $236.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ASND's P/E ratio is -98.18. In terms of profitability, OKUR's ROE is -0.49%, compared to ASND's ROE of +1.90%. Regarding short-term risk, OKUR is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
OKUR vs NBIX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, NBIX has a market cap of 14.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while NBIX trades at $142.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas NBIX's P/E ratio is 20.80. In terms of profitability, OKUR's ROE is -0.49%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, OKUR is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
OKUR vs EXEL Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, EXEL has a market cap of 14.4B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while EXEL trades at $58.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas EXEL's P/E ratio is 16.35. In terms of profitability, OKUR's ROE is -0.49%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, OKUR is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
OKUR vs SMMT Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, SMMT has a market cap of 13.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while SMMT trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas SMMT's P/E ratio is -15.09. In terms of profitability, OKUR's ROE is -0.49%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, OKUR is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
OKUR vs HALO Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, HALO has a market cap of 13.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while HALO trades at $114.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas HALO's P/E ratio is 20.79. In terms of profitability, OKUR's ROE is -0.49%, compared to HALO's ROE of +1.81%. Regarding short-term risk, OKUR is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
OKUR vs BBIO Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while BBIO trades at $69.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas BBIO's P/E ratio is -17.80. In terms of profitability, OKUR's ROE is -0.49%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, OKUR is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
OKUR vs KRTX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas KRTX's P/E ratio is -28.09. In terms of profitability, OKUR's ROE is -0.49%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, OKUR is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
OKUR vs BMRN Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while BMRN trades at $63.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas BMRN's P/E ratio is 30.80. In terms of profitability, OKUR's ROE is -0.49%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, OKUR is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
OKUR vs MDGL Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while MDGL trades at $523.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas MDGL's P/E ratio is -40.78. In terms of profitability, OKUR's ROE is -0.49%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, OKUR is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
OKUR vs TECH Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while TECH trades at $72.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas TECH's P/E ratio is 37.36. In terms of profitability, OKUR's ROE is -0.49%, compared to TECH's ROE of +0.09%. Regarding short-term risk, OKUR is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
OKUR vs RNAM Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas RNAM's P/E ratio is -17.39. In terms of profitability, OKUR's ROE is -0.49%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, OKUR is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
OKUR vs AXSM Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while AXSM trades at $204.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas AXSM's P/E ratio is -53.65. In terms of profitability, OKUR's ROE is -0.49%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, OKUR is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check AXSM's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
OKUR vs TWST Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, TWST has a market cap of 10.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while TWST trades at $167.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas TWST's P/E ratio is -74.69. In terms of profitability, OKUR's ROE is -0.49%, compared to TWST's ROE of -0.30%. Regarding short-term risk, OKUR is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check TWST's competition here
10x Genomics, Inc. (NASDAQ: TXG)
OKUR vs TXG Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, TXG has a market cap of 10B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while TXG trades at $80.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas TXG's P/E ratio is -134.07. In terms of profitability, OKUR's ROE is -0.49%, compared to TXG's ROE of -0.09%. Regarding short-term risk, OKUR is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check TXG's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
OKUR vs KRYS Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while KRYS trades at $350.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas KRYS's P/E ratio is 41.84. In terms of profitability, OKUR's ROE is -0.49%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, OKUR is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check KRYS's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
OKUR vs ARWR Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ARWR has a market cap of 9.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ARWR trades at $71.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ARWR's P/E ratio is -30.57. In terms of profitability, OKUR's ROE is -0.49%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, OKUR is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check ARWR's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
OKUR vs KYMR Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while KYMR trades at $121.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas KYMR's P/E ratio is -36.77. In terms of profitability, OKUR's ROE is -0.49%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, OKUR is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
OKUR vs RXDX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas RXDX's P/E ratio is -56.47. In terms of profitability, OKUR's ROE is -0.49%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, OKUR is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
OKUR vs PTGX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, PTGX has a market cap of 9.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while PTGX trades at $145.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas PTGX's P/E ratio is 140.76. In terms of profitability, OKUR's ROE is -0.49%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, OKUR is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
OKUR vs NUVL Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas NUVL's P/E ratio is -21.79. In terms of profitability, OKUR's ROE is -0.49%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, OKUR is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
OKUR vs CRNX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CRNX's P/E ratio is -16.86. In terms of profitability, OKUR's ROE is -0.49%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, OKUR is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check CRNX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
OKUR vs IBRX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while IBRX trades at $9.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas IBRX's P/E ratio is -8.71. In terms of profitability, OKUR's ROE is -0.49%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, OKUR is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
OKUR vs TGTX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, TGTX has a market cap of 8.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while TGTX trades at $58.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas TGTX's P/E ratio is 20.71. In terms of profitability, OKUR's ROE is -0.49%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, OKUR is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check TGTX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
OKUR vs IMGN Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas IMGN's P/E ratio is -111.55. In terms of profitability, OKUR's ROE is -0.49%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, OKUR is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check IMGN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
OKUR vs CAI Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CAI has a market cap of 8.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CAI trades at $31.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CAI's P/E ratio is 86.12. In terms of profitability, OKUR's ROE is -0.49%, compared to CAI's ROE of +0.19%. Regarding short-term risk, OKUR is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check CAI's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
OKUR vs PCVX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, PCVX has a market cap of 8.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while PCVX trades at $59.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas PCVX's P/E ratio is -7.72. In terms of profitability, OKUR's ROE is -0.49%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, OKUR is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check PCVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
OKUR vs CYTK Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CYTK has a market cap of 8.4B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CYTK trades at $67.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CYTK's P/E ratio is -9.36. In terms of profitability, OKUR's ROE is -0.49%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, OKUR is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check CYTK's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
OKUR vs BPMC Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas BPMC's P/E ratio is -51.58. In terms of profitability, OKUR's ROE is -0.49%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, OKUR is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
OKUR vs APGE Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas APGE's P/E ratio is -31.19. In terms of profitability, OKUR's ROE is -0.49%, compared to APGE's ROE of -0.30%. Regarding short-term risk, OKUR is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check APGE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
OKUR vs PRAX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while PRAX trades at $299.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas PRAX's P/E ratio is -23.11. In terms of profitability, OKUR's ROE is -0.49%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, OKUR is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
OKUR vs CERE Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CERE's P/E ratio is -16.47. In terms of profitability, OKUR's ROE is -0.49%, compared to CERE's ROE of -0.72%. Regarding short-term risk, OKUR is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
OKUR vs SYRE Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, SYRE has a market cap of 8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while SYRE trades at $91.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas SYRE's P/E ratio is -47.19. In terms of profitability, OKUR's ROE is -0.49%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, OKUR is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
OKUR vs IMVT Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while IMVT trades at $37.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas IMVT's P/E ratio is -13.18. In terms of profitability, OKUR's ROE is -0.49%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, OKUR is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check IMVT's competition here
Abivax S.A. (NASDAQ: ABVX)
OKUR vs ABVX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ABVX trades at $98.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ABVX's P/E ratio is -19.69. In terms of profitability, OKUR's ROE is -0.49%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, OKUR is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
OKUR vs IONS Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, IONS has a market cap of 7.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while IONS trades at $46.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas IONS's P/E ratio is -13.73. In terms of profitability, OKUR's ROE is -0.49%, compared to IONS's ROE of -1.11%. Regarding short-term risk, OKUR is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check IONS's competition here
Metsera, Inc. (NASDAQ: MTSR)
OKUR vs MTSR Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas MTSR's P/E ratio is -23.58. In terms of profitability, OKUR's ROE is -0.49%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, OKUR is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check MTSR's competition here
Belite Bio, Inc (NASDAQ: BLTE)
OKUR vs BLTE Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, BLTE has a market cap of 7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while BLTE trades at $175.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas BLTE's P/E ratio is -92.73. In terms of profitability, OKUR's ROE is -0.49%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, OKUR is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check BLTE's competition here
CG Oncology Inc. (NASDAQ: CGON)
OKUR vs CGON Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CGON has a market cap of 6.9B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CGON trades at $78.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CGON's P/E ratio is -29.09. In terms of profitability, OKUR's ROE is -0.49%, compared to CGON's ROE of -0.25%. Regarding short-term risk, OKUR is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
OKUR vs MRUS Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas MRUS's P/E ratio is -17.05. In terms of profitability, OKUR's ROE is -0.49%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, OKUR is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
OKUR vs RYTM Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while RYTM trades at $99.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas RYTM's P/E ratio is -31.78. In terms of profitability, OKUR's ROE is -0.49%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, OKUR is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
OKUR vs ACLX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ACLX's P/E ratio is -28.27. In terms of profitability, OKUR's ROE is -0.49%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, OKUR is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
OKUR vs RETA Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas RETA's P/E ratio is -66.29. In terms of profitability, OKUR's ROE is -0.49%, compared to RETA's ROE of +0.47%. Regarding short-term risk, OKUR is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
OKUR vs CNTA Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CNTA's P/E ratio is -22.63. In terms of profitability, OKUR's ROE is -0.49%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, OKUR is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
OKUR vs TVTX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while TVTX trades at $60.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas TVTX's P/E ratio is -139.69. In terms of profitability, OKUR's ROE is -0.49%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, OKUR is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check TVTX's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
OKUR vs LGND Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while LGND trades at $297.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas LGND's P/E ratio is 31.84. In terms of profitability, OKUR's ROE is -0.49%, compared to LGND's ROE of +0.20%. Regarding short-term risk, OKUR is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
OKUR vs SRRK Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while SRRK trades at $51.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas SRRK's P/E ratio is -13.96. In terms of profitability, OKUR's ROE is -0.49%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, OKUR is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check SRRK's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
OKUR vs ORKA Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ORKA trades at $94.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ORKA's P/E ratio is -48.13. In terms of profitability, OKUR's ROE is -0.49%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, OKUR is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check ORKA's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
OKUR vs CRSP Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CRSP trades at $59.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CRSP's P/E ratio is -12.25. In terms of profitability, OKUR's ROE is -0.49%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, OKUR is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check CRSP's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
OKUR vs CDTX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CDTX's P/E ratio is -19.77. In terms of profitability, OKUR's ROE is -0.49%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, OKUR is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
OKUR vs MIRM Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while MIRM trades at $90.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas MIRM's P/E ratio is -6.32. In terms of profitability, OKUR's ROE is -0.49%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, OKUR is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check MIRM's competition here
Abcam plc (NASDAQ: ABCM)
OKUR vs ABCM Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, OKUR's ROE is -0.49%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, OKUR is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
OKUR vs ISEE Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ISEE's P/E ratio is -22.44. In terms of profitability, OKUR's ROE is -0.49%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, OKUR is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check ISEE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
OKUR vs COGT Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while COGT trades at $32.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas COGT's P/E ratio is -15.17. In terms of profitability, OKUR's ROE is -0.49%, compared to COGT's ROE of -0.73%. Regarding short-term risk, OKUR is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
OKUR vs PTCT Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while PTCT trades at $66.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas PTCT's P/E ratio is -28.01. In terms of profitability, OKUR's ROE is -0.49%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, OKUR is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check PTCT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
OKUR vs DNTH Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while DNTH trades at $97.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas DNTH's P/E ratio is -23.25. In terms of profitability, OKUR's ROE is -0.49%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, OKUR is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check DNTH's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
OKUR vs APLS Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas APLS's P/E ratio is 38.35. In terms of profitability, OKUR's ROE is -0.49%, compared to APLS's ROE of +0.40%. Regarding short-term risk, OKUR is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
OKUR vs ERAS Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ERAS has a market cap of 5.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ERAS trades at $15.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ERAS's P/E ratio is -16.17. In terms of profitability, OKUR's ROE is -0.49%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, OKUR is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check ERAS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
OKUR vs DFTX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while DFTX trades at $39.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas DFTX's P/E ratio is N/A. In terms of profitability, OKUR's ROE is -0.49%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, OKUR is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check DFTX's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
OKUR vs EWTX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while EWTX trades at $45.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas EWTX's P/E ratio is -24.13. In terms of profitability, OKUR's ROE is -0.49%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, OKUR is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
OKUR vs TERN Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas TERN's P/E ratio is -51.41. In terms of profitability, OKUR's ROE is -0.49%, compared to TERN's ROE of -0.20%. Regarding short-term risk, OKUR is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check TERN's competition here
Veradermics, Incorporated (NYSE: MANE)
OKUR vs MANE Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while MANE trades at $117.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas MANE's P/E ratio is -35.94. In terms of profitability, OKUR's ROE is -0.49%, compared to MANE's ROE of -0.38%. Regarding short-term risk, OKUR is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
OKUR vs FOLD Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas FOLD's P/E ratio is -161.00. In terms of profitability, OKUR's ROE is -0.49%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, OKUR is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check FOLD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
OKUR vs IOVA Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, IOVA has a market cap of 4.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while IOVA trades at $10.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas IOVA's P/E ratio is -13.96. In terms of profitability, OKUR's ROE is -0.49%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, OKUR is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check IOVA's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
OKUR vs ACAD Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ACAD trades at $26.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ACAD's P/E ratio is 11.89. In terms of profitability, OKUR's ROE is -0.49%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, OKUR is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check ACAD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
OKUR vs AKRO Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas AKRO's P/E ratio is -14.57. In terms of profitability, OKUR's ROE is -0.49%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, OKUR is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check AKRO's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
OKUR vs ADPT Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ADPT trades at $28.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ADPT's P/E ratio is -67.95. In terms of profitability, OKUR's ROE is -0.49%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, OKUR is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check ADPT's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
OKUR vs ALPN Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ALPN's P/E ratio is -101.52. In terms of profitability, OKUR's ROE is -0.49%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, OKUR is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check ALPN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
OKUR vs PBLS Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while PBLS trades at $38.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas PBLS's P/E ratio is -19.64. In terms of profitability, OKUR's ROE is -0.49%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, OKUR is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
OKUR vs OPT Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas OPT's P/E ratio is -1.52. In terms of profitability, OKUR's ROE is -0.49%, compared to OPT's ROE of +1.18%. Regarding short-term risk, OKUR is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
OKUR vs PRTC Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas PRTC's P/E ratio is -3.78. In terms of profitability, OKUR's ROE is -0.49%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, OKUR is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
OKUR vs MRTX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas MRTX's P/E ratio is -4.82. In terms of profitability, OKUR's ROE is -0.49%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, OKUR is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
OKUR vs CELC Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CELC trades at $84.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CELC's P/E ratio is -19.53. In terms of profitability, OKUR's ROE is -0.49%, compared to CELC's ROE of -3.51%. Regarding short-term risk, OKUR is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check CELC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
OKUR vs RLAY Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while RLAY trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas RLAY's P/E ratio is -11.59. In terms of profitability, OKUR's ROE is -0.49%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, OKUR is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check RLAY's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
OKUR vs ABCL Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while ABCL trades at $12.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas ABCL's P/E ratio is -23.44. In terms of profitability, OKUR's ROE is -0.49%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, OKUR is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
OKUR vs CPRX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CPRX's P/E ratio is 12.30. In terms of profitability, OKUR's ROE is -0.49%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, OKUR is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check CPRX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
OKUR vs TLX Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while TLX trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas TLX's P/E ratio is 118.06. In terms of profitability, OKUR's ROE is -0.49%, compared to TLX's ROE of +0.07%. Regarding short-term risk, OKUR is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check TLX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
OKUR vs XENE Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while XENE trades at $38.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas XENE's P/E ratio is -8.30. In terms of profitability, OKUR's ROE is -0.49%, compared to XENE's ROE of -0.44%. Regarding short-term risk, OKUR is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for OKUR.Check XENE's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
OKUR vs RYZB Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas RYZB's P/E ratio is -57.86. In terms of profitability, OKUR's ROE is -0.49%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, OKUR is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
OKUR vs CBAY Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas CBAY's P/E ratio is -32.81. In terms of profitability, OKUR's ROE is -0.49%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, OKUR is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check CBAY's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
OKUR vs IDYA Comparison September 2026
OnKure Therapeutics, Inc. (NASDAQ: OKUR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OKUR stands at 123.9M. In comparison, IDYA has a market cap of 3.7B. Regarding current trading prices, OKUR is priced at $3.09 on the NASDAQ, while IDYA trades at $39.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OKUR currently has a P/E ratio of -0.87, whereas IDYA's P/E ratio is -20.03. In terms of profitability, OKUR's ROE is -0.49%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, OKUR is more volatile compared to IDYA. This indicates higher risk in terms of short-term price fluctuations for OKUR.Check IDYA's competition here